Your browser doesn't support javascript.
loading
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
Ray, Kausik K; Molemans, Bart; Schoonen, W Marieke; Giovas, Periklis; Bray, Sarah; Kiru, Gaia; Murphy, Jennifer; Banach, Maciej; De Servi, Stefano; Gaita, Dan; Gouni-Berthold, Ioanna; Hovingh, G Kees; Jozwiak, Jacek J; Jukema, J Wouter; Kiss, Robert Gabor; Kownator, Serge; Iversen, Helle K; Maher, Vincent; Masana, Luis; Parkhomenko, Alexander; Peeters, André; Clifford, Piers; Raslova, Katarina; Siostrzonek, Peter; Romeo, Stefano; Tousoulis, Dimitrios; Vlachopoulos, Charalambos; Vrablik, Michal; Catapano, Alberico L; Poulter, Neil R.
Afiliação
  • Ray KK; Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
  • Molemans B; Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Schoonen WM; Center for Observational Research (CfOR), Amgen Ltd, 1 Uxbridge Business Park Sanderson Road, Uxbridge, UB8 1DH, UK.
  • Giovas P; Amgen Hellas, 4 Gravias Street, Maroussi, 15125, Athens, Greece.
  • Bray S; Global Biostatistical Science, Amgen Ltd, 240 Cambridge Science Park, Milton Road, Cambridge, CB4 0WD, UK.
  • Kiru G; Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
  • Murphy J; Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London W12 7RH, UK.
  • Banach M; Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, 90-419 Lodz, Poland.
  • De Servi S; Polish Mother's Memorial Hospital - Research Institute (PMMHRI), 93-338 Lodz, Poland.
  • Gaita D; Cardiovascular Research Centre, University of Zielona Góra, 65-417 Zielona Góra, Poland.
  • Gouni-Berthold I; IRCCS MultiMedica, Via Milanese, 300, 20099 Sesto San Giovanni, Milan, Italy.
  • Hovingh GK; Institutul de Boli Cardiovasculare, Fundatia Cardioprevent, Universitatea de Medicina si Farmacie Victor Babes din Timisoara, Timisoara 300041, Romania.
  • Jozwiak JJ; Polyclinic for Endocrinology, Diabetes and Preventive Medicine, Kerpener Str. 62, 50937 Cologne, Germany.
  • Jukema JW; University of Amsterdam Faculty of Medicine, Amsterdam, the Netherlands.
  • Kiss RG; Department of Family Medicine and Public Health, Faculty of Medicine, University of Opole, Opole, Poland.
  • Kownator S; Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, Netherlands.
  • Iversen HK; Hungarian Army Medical Center, Budapest, 1134, Hungary.
  • Maher V; Centre Cardiologique et Vasculaire, 36 Route de la Briquerie, 57100, Thionville, France.
  • Masana L; Stroke Centre Rigshospitalet, Department of Neurology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
  • Parkhomenko A; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Peeters A; Trinity College Dublin, Dublin 2, Ireland.
  • Clifford P; Advanced Lipid Management and Research Centre, Tallaght University Hospital, Dublin 24, Ireland.
  • Raslova K; Universitat Rovira i Virgili, IISPV, CIBERDEM, Saint Joan University Hospital, Reus, Spain.
  • Siostrzonek P; Emergency Cardiology Department, Institute of Cardiology, Kiev, Ukraine.
  • Romeo S; Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium.
  • Tousoulis D; Imperial Hospitals NHS Trust (Hammersmith Campus), London W12 0HS, UK.
  • Vlachopoulos C; Slovak Medical University, 831 01 Bratislava, Slovakia.
  • Vrablik M; Krankenhaus Barmherzige Schwestern Linz, Seilerstðtte 4, 4010 Seilerstätte 4, 4010 Linz, Austria.
  • Catapano AL; Department of Molecular and Clinical Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden.
  • Poulter NR; Clinical Nutrition, Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy.
Eur J Prev Cardiol ; 28(11): 1279-1289, 2021 09 20.
Article em En | MEDLINE | ID: mdl-33580789
AIMS: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. METHODS AND RESULTS: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52-56] achieved their risk-based 2016 goal and 33% (95% CI 32-35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate-high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination). CONCLUSION: Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Dislipidemias / Anticolesterolemiantes Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Dislipidemias / Anticolesterolemiantes Idioma: En Ano de publicação: 2021 Tipo de documento: Article